Join
Live feed
·
PRReleasevia Quantisnow
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)

ByQuantisnow·Wall Street's wire, on your screen.
TNXP· Tonix Pharmaceuticals Holding Corp.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TNXP (Tonix Pharmaceuticals Holding Corp.) and more on Quantisnow.